GLP-1tirzepatidechronic kidney diseasetype 2 diabetesalbuminuria

Tirzepatide cuts albuminuria in 62 nephrology patients with CKD and diabetes

Median urinary albumin-to-creatinine ratio fell from 111 to 44 mg/mmol over 21.4 weeks while eGFR stayed stable, the UK clinic cohort reports.

By Maren Holt · Senior Reporter, GLP-1

Oct 18 20:00 ETSource: Diabetic medicine : a journal of the British Diabetic Association

The wire

01In 62 adults with CKD stages 1-5 and type 2 diabetes plus obesity, tirzepatide reduced median weight from 103 to 100 kg, HbA1c from 63 to 54 mmol/mol, and uACR from 111 to 44 mg/mmol.
02Prescribers have had little real-world safety data on tirzepatide in advanced CKD; eGFR remained stable and insulin requirements fell in this multi-ethnic clinic cohort.
03Observational, single-centre, 62 patients, median follow-up 21.4 weeks; gastrointestinal symptoms and decreased serum bicarbonate were the most common adverse events, and authors urge multidisciplinary oversight.

From the source

Real-world observational study evaluating metabolic and kidney outcomes in patients living with chronic kidney disease and type 2 diabetes mellitus with obesity prescribed tirzepatide
Diabetic medicine : a journal of the British Diabetic Association · 2026 Oct 19 · Carruthers JE, Ooi XY, Goodall D et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42897718/